Lisuride in parkinsonism
Identifieur interne : 002B48 ( Main/Exploration ); précédent : 002B47; suivant : 002B49Lisuride in parkinsonism
Auteurs : J. D. Parkes ; M. Schachter ; C. D. Marsden ; B. Smith [Royaume-Uni] ; A. Wilson [Royaume-Uni]Source :
- Annals of Neurology [ 0364-5134 ] ; 1981-01.
Abstract
Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug‐induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressive supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.
Url:
DOI: 10.1002/ana.410090109
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lisuride in parkinsonism</title><author><name sortKey="Parkes, J D" sort="Parkes, J D" uniqKey="Parkes J" first="J. D." last="Parkes">J. D. Parkes</name></author><author><name sortKey="Schachter, M" sort="Schachter, M" uniqKey="Schachter M" first="M." last="Schachter">M. Schachter</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author><author><name sortKey="Smith, B" sort="Smith, B" uniqKey="Smith B" first="B." last="Smith">B. Smith</name></author><author><name sortKey="Wilson, A" sort="Wilson, A" uniqKey="Wilson A" first="A." last="Wilson">A. Wilson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DCB36F727167E48678FBBB1D49222B1BA5A191A8</idno><date when="1981" year="1981">1981</date><idno type="doi">10.1002/ana.410090109</idno><idno type="url">https://api.istex.fr/document/DCB36F727167E48678FBBB1D49222B1BA5A191A8/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A56</idno><idno type="wicri:Area/Main/Curation">001798</idno><idno type="wicri:Area/Main/Exploration">002B48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Lisuride in parkinsonism</title><author><name sortKey="Parkes, J D" sort="Parkes, J D" uniqKey="Parkes J" first="J. D." last="Parkes">J. D. Parkes</name><affiliation><wicri:noCountry code="subField">London SE5 9RS</wicri:noCountry></affiliation></author><author><name sortKey="Schachter, M" sort="Schachter, M" uniqKey="Schachter M" first="M." last="Schachter">M. Schachter</name><affiliation><wicri:noCountry code="subField">London SE5 9RS</wicri:noCountry></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation><wicri:noCountry code="subField">London SE5 9RS</wicri:noCountry></affiliation></author><author><name sortKey="Smith, B" sort="Smith, B" uniqKey="Smith B" first="B." last="Smith">B. Smith</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Clinical Laboratories of the Maudsley and Bethlem Royal Hospitals, Maudsley Hospital, London SE5 8AZ</wicri:cityArea></affiliation></author><author><name sortKey="Wilson, A" sort="Wilson, A" uniqKey="Wilson A" first="A." last="Wilson">A. Wilson</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Clinical Laboratories of the Maudsley and Bethlem Royal Hospitals, Maudsley Hospital, London SE5 8AZ</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1981-01">1981-01</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="48">48</biblScope><biblScope unit="page" to="52">52</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">DCB36F727167E48678FBBB1D49222B1BA5A191A8</idno><idno type="DOI">10.1002/ana.410090109</idno><idno type="ArticleID">ANA410090109</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug‐induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressive supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><noCountry><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Parkes, J D" sort="Parkes, J D" uniqKey="Parkes J" first="J. D." last="Parkes">J. D. Parkes</name><name sortKey="Schachter, M" sort="Schachter, M" uniqKey="Schachter M" first="M." last="Schachter">M. Schachter</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Smith, B" sort="Smith, B" uniqKey="Smith B" first="B." last="Smith">B. Smith</name></region><name sortKey="Wilson, A" sort="Wilson, A" uniqKey="Wilson A" first="A." last="Wilson">A. Wilson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DCB36F727167E48678FBBB1D49222B1BA5A191A8
|texte= Lisuride in parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |